文献速递胸部肿瘤

新抗原DC疫苗联合CpG将小鼠肺癌「冷」肿瘤转为「热」肿瘤

[LLC1 neoantigen dendritic cell vaccination combined with CpG effectively converts "cold" tumors into "hot" tumors in murine lung cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

该研究通过全外显子组和RNA测序筛选LLC1细胞新抗原,制备新抗原负载DC疫苗,并在LLC1荷瘤小鼠中评估联合CpG的疗效。结果显示LLC1-M02具有强免疫原性,LLC1-M02-DC疫苗联合CpG显著抑制肿瘤生长并延长中位生存期至79.0天。

要点

  • 新抗原LLC1-M02诱导的CD3+IFN-γ+T细胞百分数为13.81±3.00%,高于无关肽的1.00±0.30%。
  • LLC1-M02-DC联合CpG组中位生存期79.0天,长于LLC1-M02-DC组的55.0天(P=0.008)。
  • 联合组肿瘤生长抑制强于LLC1-M02-DC单药组(P<0.001),各组体重无明显差异。

核心结论

  • 小鼠LLC1细胞系新抗原LLC1-M02具有强免疫原性,LLC1-M02-DC疫苗联合CpG可增强对肺癌「冷」肿瘤的抑制作用。

研究设计与样本

  • 对LLC1细胞行全外显子组和RNA测序,用NetMHCpan v4.0和NetMHCⅡpan v3.2预测新抗原与MHC结合亲和力,合成LLC1-M01至M05五条候选新抗原。
  • 在C57BL/6小鼠皮下接种候选新抗原,用流式细胞术和ELISPOT评估免疫原性,制备新抗原负载DC疫苗。
  • 在LLC1荷瘤小鼠模型中比较未负载DC疫苗、CpG、LLC1-M02-DC、LLC1-M02-WT-DC和LLC1-M02-DC+CpG各组,监测T细胞亚群、穿孔素/颗粒酶、肿瘤体积、体重和生存时间。

主要发现

  • LLC1-M01和LLC1-M02诱导的CD3+IFN-γ+T细胞百分数分别为(4.80±1.00)%和(13.81±3.00)%,均高于VSV-NP43-69的(1.00±0.30)%(均P<0.001)。
  • LLC1-M02诱导效应脾细胞分泌IFN-γ为(820.00±200.00)SFU/105细胞,高于LLC1-M02-WT的(430.00±100.00)SFU/105细胞(P<0.001);LLC1-M01与LLC1-M01-WT差异无统计学意义(P=0.753)。
  • 效靶比50∶1时,LLC1-M02-DC诱导的效应T细胞对LLC1细胞特异性杀伤率为(35.02±8.00)%,高于对MC38和B16-F10细胞(P<0.001),也高于M02-WT诱导的(20.01±4.00)%(P<0.001)。
  • 与无CpG组相比,CpG组肿瘤组织中CD3+CD8+、CD3+穿孔素+、CD3+颗粒酶+、CD8+穿孔素+、CD8+颗粒酶+T细胞百分数均增高(均P<0.01),TNF-α、IFN-γ、IL-2和IL-12表达下调(均P<0.01),IL-10和IL-13表达上调(均P<0.01)。
  • 未负载DC疫苗组、CpG组、LLC1-M02-DC组、LLC1-M02-WT-DC组和LLC1-M02-DC+CpG组中位生存时间分别为28.0、30.5、55.0、37.5和79.0天;LLC1-M02-DC组生存长于LLC1-M02-WT-DC组(P=0.045),短于联合组(P=0.008);联合组肿瘤生长抑制强于LLC1-M02-DC组(P<0.001),各组体重无明显差异。

临床怎么用

  • 该研究为小鼠临床前模型,提示新抗原DC疫苗联合CpG可能作为肺癌免疫「冷」肿瘤的潜在策略,尚需临床转化验证。

局限性

  • 研究仅基于小鼠LLC1细胞系和C57BL/6小鼠模型,结论外推至人体需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore a novel strategy for treating immunologically "cold" lung tumors by combining neoantigen-pulsed dendritic cell (DC) vaccines with CpG. Methods: LLC1 cells were analyzed by whole-exome sequencing and RNA sequencing. Tumor-specific nonsynonymous mutations were identified using RNA sequencing data, and candidate neoantigens were screened by predicting their binding affinity to major histocompatibility complex molecules using NetMHCpan v4.0 and NetMHCⅡpan v3.2. Neoantigens LLC1-M01, LLC1-M02, LLC1-M03, LLC1-M04, and LLC1-M05 were synthesized via Fmoc solid-phase peptide synthesis. Candidate neoantigens were subcutaneously inoculated into C57BL/6 mice. Neoantigen immunogenicity was assessed using flow cytometry, and interferon-gamma (IFN-γ) secretion by effector T cells was measured via enzyme-linked immunospot assay. A neoantigen-pulsed DC vaccine was prepared. Changes in immune cells and cytokines within the tumor microenvironment were measured using flow cytometry and enzyme-linked immunosorbent assay (ELISA). In a lung cancer LLC1 cell tumor-bearing mouse model, treatments included unpulsed DC vaccine, CpG, LLC1-M02-DC, LLC1-M02-WT-DC, and LLC1-M02-DC+CpG. The percentages of CD3+CD4+ and CD3+CD8+ T cells, perforin and granzyme expression in CD3+ or CD8+ T cells in tumor tissues, as well as tumor volume, mouse body weight changes, and survival time were monitored. Results: The percentages of CD3+IFN-γ+ T cells induced by neoantigens LLC1-M01 and LLC1-M02 were (4.80±1.00)% and (13.81±3.00)%, respectively, which were higher than that induced by the irrelevant peptide VSV-NP43-69 [(1.00±0.30)%; both P<0.001]. The IFN-γ secretion capacity of effector splenocytes induced by LLC1-M01 was (200.00±45.00) spot-forming units (SFU)/105 cells, showing no significant difference from LLC1-M01-WT [(193.00±42.00) SFU/105 cells; P=0.753]. In contrast, IFN-γ secretion induced by LLC1-M02 was (820.00±200.00) SFU/105 cells, significantly higher than that induced by LLC1-M02-WT [(430.00±100.00) SFU/105 cells; P<0.001]. At an effector-to-target ratio of 50:1, the specific killing rate of LLC1 cells by effector T cells induced by LLC1-M02-DC was (35.02±8.00)%, which was higher than the rates of killing against MC38 and B16-F10 cells (P<0.001), and also higher than that induced by M02-WT against LLC1 cells [(20.01±4.00)%; P<0.001]. Compared with the no-CpG group, the CpG group showed increased percentages of CD3+CD8+, CD3+perforin+, CD3+granzyme+, CD8+perforin+, and CD8+granzyme+ T cells in tumor tissue (all P<0.01), downregulated expression of tumor necrosis factor-alpha (TNF-α), IFN-γ, interleukin (IL)-2, and IL-12 (all P<0.01), and upregulated expression of IL-10 and IL-13 (all P<0.01). In tumor-bearing mice treatment experiments, compared with the unpulsed DC vaccine group, CpG group, and LLC1-M02-WT-DC group, tumor growth was significantly inhibited in the LLC1-M02-DC group. The LLC1-M02-DC+CpG group exhibited stronger tumor growth inhibition than the LLC1-M02-DC group (P<0.001), while no significant differences in body weight were observed among groups. The median survival times of tumor-bearing mice in the unpulsed DC vaccine, CpG, LLC1-M02-DC, LLC1-M02-WT-DC, and LLC1-M02-DC+CpG groups were 28.0, 30.5, 55.0, 37.5, and 79.0 days, respectively. Survival time in the LLC1-M02-DC group was significantly longer than that in the LLC1-M02-WT-DC group (P=0.045) but significantly shorter than that in the LLC1-M02-DC+CpG group (P=0.008). Conclusions: The neoantigen LLC1-M02 from the murine LLC1 cell line exhibits strong immunogenicity. The LLC1-M02-DC vaccine combined with CpG enhances the inhibitory effect on lung "cold" tumors. 目的: 探究新抗原树突状细胞(DC)疫苗联合CpG治疗肺癌免疫“冷”肿瘤的新策略。 方法: 对肺癌LLC1细胞进行全外显子组二代测序和RNA测序,利用RNA测序数据鉴定肿瘤特异性非同义突变表达,通过NetMHCpanv 4.0和NetMHCⅡpan 3.2预测新抗原与主要组织相容性复合体分子的结合亲和力,筛选候选新抗原。采用芴甲氧羰基化学合成法合成新抗原LLC1-M01、LLC1-M02、LLC1-M03、LLC1-M04和LLC1-M05。分别在C57BL/6小鼠皮下接种候选新抗原,采用流式细胞术进行新抗原免疫原性鉴定,采用酶联免疫斑点方法检测效应T细胞的γ-干扰素(IFN-γ)分泌。基于多肽制备新抗原DC疫苗。利用流式细胞术和酶联免疫吸附试验(ELISA)测定肿瘤微环境中免疫细胞和细胞因子变化。在肺癌LLC1细胞荷瘤鼠模型分别接种未负载多肽DC疫苗、CpG、LLC1-M02-DC、LLC1-M02-WT-DC和LLC1-M02-DC+CpG,检测肿瘤组织检测CD3+ CD4+和CD3+ CD8+ T细胞百分数、CD3+ T细胞或CD8+ T细胞穿孔素和颗粒酶的表达,观察肿瘤体积和小鼠体重的变化及小鼠的生存时间。 结果: 新抗原LLC1-M01和LLC1-M02诱导的CD3+ IFN-γ+ T细胞百分数分别为(4.80±1.00)%和(13.81±3.00)%,高于无关肽水疱性口炎病毒载体表达的流感病毒核蛋白43~69位氨基酸片段(VSV-NP43-69)的(1.00±0.30)%(均P<0.001)。LLC1-M01诱导的效应脾细胞分泌IFN-γ的能力为(200.00±45.00)斑点形成单位(SFU)/105个细胞,与LLC1-M01-WT[(193.00±42.00)SFU/105个细胞]差异无统计学意义(P=0.753);而LLC1-M02诱导的效应脾细胞分泌IFN-γ的能力为(820.00±200.00)SFU/105个细胞,高于LLC1-M02-WT[(430.00±100.00)SFU/105个细胞;P<0.001]。当效靶比为50∶1时,LLC1-M02-DC诱导的效应T细胞对LLC1细胞的特异性杀伤率为(35.02±8.00)%,高于对MC38细胞和对B16-F10细胞的特异性杀伤率(P<0.001),也高于M02-WT诱导的T细胞对LLC1细胞的特异性杀伤率[(20.01±4.00)%,P<0.001]。与无CpG组相比,CpG组肿瘤组织中CD3+ CD8+、CD3+ 穿孔素+、CD3+ 颗粒酶+、CD8+ 穿孔素+、CD8+ 颗粒酶+ T细胞百分数均增高(均P<0.01),肿瘤坏死因子α、IFN-γ、白细胞介素(IL)-2和IL-12表达下调(均P<0.01),而IL-10和IL-13表达上调(均P<0.01)。荷瘤小鼠治疗实验显示,与未负载多肽DC疫苗组、CpG组和LLC1-M02-WT-DC组相比,LLC1-M02-DC组荷瘤小鼠肿瘤生长明显受到抑制,LLC1-M02-DC+CpG组对肿瘤生长的抑制效应比LLC1-M02-DC组更强(P<0.001),而各组小鼠的体重无明显差异。未负载多肽DC疫苗组、CpG组、LLC1-M02-DC组、LLC1-M02-WT-DC组和LLC1-M02-DC+CpG组荷瘤小鼠的中位生存时间分别为28.0、30.5、55.0、37.5和79.0 d,其中LLC1-M02-DC组荷瘤小鼠的生存时间比LLC1-M02-WT-DC组明显延长(P=0.045),但比LLC1-M02-DC+CpG组明显缩短(P=0.008)。 结论: 小鼠LLC1细胞系中的新抗原LLC1-M02具有强免疫原性,LLC1-M02-DC疫苗与CpG联合可增强对肺癌“冷”肿瘤的抑制作用。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Gao J, Song J, Wei XF, et al. [LLC1 neoantigen dendritic cell vaccination combined with CpG effectively converts "cold" tumors into "hot" tumors in murine lung cancer]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 41688207. doi:10.3760/cma.j.cn112152-20250611-00268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。